Cite
HARVARD Citation
Daneshvar, E. et al. (2023). Elevated serum level of B‐cell activating factor (BAFF) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B‐cell depletion therapies combined with anti‐BAFF agents. International journal of dermatology. pp. 567-574. [Online].